Jon Markman

Jon Markman

Jon Markman is the editor of Trader’s Advantage, a daily trading service that leverages his unique swing trading principles and aims to capture profits of 7% to 15% — and often much more with his options trades — in less than 90 days. By combining technical analysis with underlying fundamentals, Jon recommends beaten down stocks on the brink of reversal and powerful momentum stocks breaking out to new highs.

In CounterPoint Options Jon helps options traders lock in consistent profits from the volatility that rocks the market. At its heart is a proprietary trading system, Magnitude, that pinpoints indexes or sectors that have reached a critical inflection point — then translates that signal into profitable trades.

CounterPoint Options keeps volatility options trading very simple, focusing on the most popular, highly traded exchange-traded funds (ETFs) that are headed for a key reversal. Magnitude scans the market and allows subscribers to take advantage of these very liquid trading opportunities.

When CounterPoint Options first launched, it was focused solely on trading the VIX, commonly known as the “fear index.” When traders start buying up put options as “portfolio insurance,” the VIX spikes — a phenomenon that we’ll either trade directly, or use to inform our ETF trades on specific slices of the market. Our agile (and highly lucrative) strategy lets us turn volatility into profits… just like professional traders and hedge funds have been doing for years.

CounterPoint Options helps individual traders make steady, consistent profits from a very methodical approach to growing your portfolio in the midst of a turbulent market.

A pioneer in the development of stock-rating systems and screening software, Jon Markman is co-inventor on two Microsoft patents and author of the best-selling books Swing Trading and Online Investing. He was portfolio manager and senior investment strategist at a multi-strategy hedge fund from 2002 to 2005; managing editor and columnist at CNBC on MSN Money from 1997 to 2002; and an editor, investment columnist and investigative reporter at the Los Angeles Times from 1984 to 1997.

Jon won a Gerald Loeb Award for Distinguished Financial Journalism for his columns explaining market chicanery in 2002; Society of Professional Journalists awards for his 2001 reporting on Enron and the post-Sept. 11-investment environment; and was a news editor on the Los Angeles Times staff that won Pulitzer Prizes for spot-news reporting in 1992 and 1994.

A graduate of Duke University and the Columbia University Graduate School of Journalism, Jon speaks frequently on investment topics at conferences nationwide, as well as on TV and radio.

Recent Articles

Trade of the Day: General Electric (GE)

I think GE will now get through its 2007 high, a milestone that most of its industrial peers passed long ago.

Best Stocks for 2016: Globant (GLOB) Is a Little-Known Dynamo

Globant (GLOB) stock is primed to be an outperformer again in 2016, according to Jon Markman.

Trade of the Day: Nvidia (NVDA)

Chip stocks tend to do really well at the end of the year and in January, and Nvidia (NVDA) should be at the front of that parade.

Trade of the Day: Banco Bradesco (BBD)

Banco Bradesco is back to the bottom of its recent range, and my work suggests that it now has a shot at moving back up.

Trade of the Day: JetBlue (JBLU)

JetBlue shares tend to fare well in December. In 2011 and 2012, in similar circumstances, the shares were up 18% and 12%, respectively, in the month.

Trade of the Day: PepsiCo (PEP)

PEP shares rose $10 from late September to late October and then pulled back. They should be back to their winning ways now.

Trade of the Day: Orbital ATK (OA)

There's a trading idea I'd like you to consider in the midst of the Paris attacks.

Trade of the Day: Xerox (XRX)

Xerox is worth much more than the current price, so this presents a good bullish opportunity.

Trade of the Day: Chevron (CVX)

Alongside Monday’s pullback in oil prices, CVX nestled into the middle of its Keltner channel. This should be a good time to buy.

Trade of the Day: Biotech Double – Mannkind (MNKD) and PDL BioPharma (PDLI)

Biotech stocks got hit hard in recent weeks as concerns about prescription drug prices mounted.